Developer docs
API playgroundTry for free, no card

Search company profiles

Micro Interventional Devices

Full company profile

uuid000338l

Namestring
Micro Interventional Devices
Legal namestring
Micro Interventional Devices, Incorporated
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewtown, United States
HQ citystring
Newtown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter heart repair, structural heart devices, percutaneous annuloplasty systems, tricuspid valve repair, mitral valve repair
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Structural Heart Repair Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

MID designs, manufactures and commercializes catheter-based technologies for structural heart disease treatment. As a pre-commercial/early commercial medical device company with products in clinical trials, revenue will come from sales of transcatheter cardiac repair devices and delivery systems to hospitals and cardiac centers following regulatory approvals (CE Mark and FDA).

microinterventional.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Micro Interventional Devices (MID) designs, manufactures and commercializes catheter-based technologies for transcatheter cardiac repair (TCR) of structural heart disease. Its core products are the MIA-T Percutaneous Tricuspid Annuloplasty System and the MIA-M Percutaneous Mitral Annuloplasty System, both built on a proprietary PolyCor anchor platform deployed through a 12F catheter to replicate surgical annuloplasty on a beating heart without cardiopulmonary bypass. The MIA-T system has FDA Breakthrough Device Designation and IDE approval for a US pivotal trial, while European clinical trial data from the STTAR study covers 31 treated patients to date.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Significant reductions in annular dimensions and tricuspid regurgitation achieved acutely with MIA-T are durable at one-year follow-up
+2 more records
Product overview1 text field

Micro Interventional Devices (MID) develops a platform of transcatheter cardiac repair (TCR) products that replicate established surgical structural heart repair procedures percutaneously. The core technology is the proprietary PolyCor anchoring system, which serves as the foundation for two main product lines: the MIA-T (for tricuspid valve repair) and MIA-M (for mitral valve repair). Both systems use 12F catheter-based delivery to deploy anchors and proprietary suture locks, enabling structural heart repair while the heart is beating without the need for cardiopulmonary bypass.

Product and service3 records
1MIA-T Percutaneous Tricuspid Annuloplasty System
CategoryStructural Heart Repair - Tricuspid
Description

Percutaneous annuloplasty system for tricuspid valve repair that replicates a surgical annuloplasty procedure on the end of a 12F catheter. Deploys proprietary PolyCor anchors and a proprietary suture lock into the tricuspid annulus in 4/1000ths of a second to reduce annular dimensions and tricuspid regurgitation. Image-guided using fluoroscopy and 2D/3D echocardiography on a beating heart without cardiopulmonary bypass. Intended for patients with tricuspid regurgitation who are ineligible for open-heart surgery. Currently an investigational device.

2MIA-M Percutaneous Mitral Annuloplasty System
CategoryStructural Heart Repair - Mitral
Description

Percutaneous annuloplasty system for mitral valve repair that places permanent cardiac implants into the mitral annulus for patients with Grade 2 or greater functional mitral regurgitation. Uses a closed-chest, beating-heart, transcatheter technique via transvenous, transseptal approach through the femoral vein. Built on the same PolyCor anchor and 12F catheter platform as MIA-T.

3PolyCor™ Anchors
CategoryProprietary Anchoring Technology Platform
Description

Proprietary ultra-low mass, biocompatible polymeric anchors specifically designed for soft-tissue cardiac applications. Deploy from catheter-based delivery systems in 4/1000ths of a second, create secure purchase in tissue, comply with wall-motion, do not back out, and include radiopaque markers for visibility on imaging. Function as the foundational anchoring component of MID's transcatheter annuloplasty systems.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Neovasc, Inc.
Strategic tierMinorTypeOthersAnnounced on2019-02-20
Description

MID reached a settlement agreement with Neovasc, Inc. in February 2019. This was a legal settlement rather than a commercial partnership.

microinterventional.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeBroad incumbent
Description

Abbott markets the TriClip transcatheter tricuspid repair system (FDA-approved) and the MitraClip system for mitral repair — directly comparable transcatheter valve repair products targeting the same patient populations and delivered via similar percutaneous catheter approaches.

TypeBroad incumbent
Description

Edwards has the Cardioband tricuspid repair system and the PASCAL mitral repair platform, making it one of the largest and most established incumbents in the percutaneous tricuspid and mitral repair space where MID competes.

TypeDirect peer
Description

Cardiac Dimensions develops the Carillon percutaneous annuloplasty system for functional mitral regurgitation — a near-direct competitor to MID's MIA-M, addressing the same indication via a transcatheter coronary sinus-based annuloplasty approach.

44Tech Cardio
TypeDirect peer
Description

4Tech Cardio is developing transcatheter tricuspid annuloplasty technology (Cardioband predecessor / similar percutaneous annular repair approach), making it a direct competitor in the same MIA-T category with overlapping clinical trial timelines and indications.

TypeDirect peer
Description

NeoChord develops transcatheter chordal repair technology for mitral regurgitation (DS1000 system via transapical delivery) — a direct peer in the percutaneous mitral repair space targeting the same pathology with a different mechanical approach.

TypeBroad incumbent
Description

Medtronic is a broad incumbent in structural heart with the Intrepid transcatheter mitral valve replacement program and a large interventional cardiology salesforce, competing for the same hospital budgets and structural heart programs as MID's MIA-T and MIA-M.

TypeEmerging player
Description

Ancora Heart is developing the AccuCinch transcatheter ventricular repair system for functional mitral regurgitation, an emerging player in the percutaneous mitral repair category with overlapping clinical positioning to MIA-M.

TypeBroad incumbent
Description

Boston Scientific is a broad medtech incumbent that has invested in structural heart programs (including transcatheter mitral investments) and serves the same hospital cardiology and cardiac surgery customers that MID targets with its TCR platform.

TypeEmerging player
Description

Cardiovalve (acquired by Venus Medtech) is developing a transcatheter tricuspid and mitral valve replacement technology — an emerging player in the structural heart repair category overlapping MID's MIA-T and MIA-M indications.

10Polaris Cardiovascular
TypeEmerging player
Description

Polaris Cardiovascular develops transcatheter tricuspid repair devices, an emerging competitor in the same percutaneous tricuspid annular repair space where MID's MIA-T competes.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micro Interventional Devices

Structural Heart Repair Devicesmicrointerventional.com

Micro Interventional Devices firmographics

Firmographics
Name
Micro Interventional Devices
Legal name
Micro Interventional Devices, Incorporated
Website
https://microinterventional.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Micro Interventional Devices industry classification

Industry
Product category
Structural Heart Repair Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Transcatheter heart repair
  • Structural heart devices
  • Percutaneous annuloplasty systems
  • Tricuspid valve repair
  • Mitral valve repair

Where Micro Interventional Devices is headquartered

Location

Headquarters

HQ city
Newtown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Micro Interventional Devices business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: MID designs, manufactures and commercializes catheter-based technologies for structural heart disease treatment. As a pre-commercial/early commercial medical device company with products in clinical trials, revenue will come from sales of transcatheter cardiac repair devices and delivery systems to hospitals and cardiac centers following regulatory approvals (CE Mark and FDA).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Micro Interventional Devices product offering

Product offering

Core offering

Micro Interventional Devices (MID) designs, manufactures and commercializes catheter-based technologies for transcatheter cardiac repair (TCR) of structural heart disease. Its core products are the MIA-T Percutaneous Tricuspid Annuloplasty System and the MIA-M Percutaneous Mitral Annuloplasty System, both built on a proprietary PolyCor anchor platform deployed through a 12F catheter to replicate surgical annuloplasty on a beating heart without cardiopulmonary bypass. The MIA-T system has FDA Breakthrough Device Designation and IDE approval for a US pivotal trial, while European clinical trial data from the STTAR study covers 31 treated patients to date.

Product overview

Micro Interventional Devices (MID) develops a platform of transcatheter cardiac repair (TCR) products that replicate established surgical structural heart repair procedures percutaneously. The core technology is the proprietary PolyCor anchoring system, which serves as the foundation for two main product lines: the MIA-T (for tricuspid valve repair) and MIA-M (for mitral valve repair). Both systems use 12F catheter-based delivery to deploy anchors and proprietary suture locks, enabling structural heart repair while the heart is beating without the need for cardiopulmonary bypass.

Differentiator

Problem solved

Functional benefit

Products and services

  • MIA-T Percutaneous Tricuspid Annuloplasty System Percutaneous annuloplasty system for tricuspid valve repair that replicates a surgical annuloplasty procedure on the end of a 12F catheter. Deploys proprietary PolyCor anchors and a proprietary suture lock into the tricuspid annulus in 4/1000ths of a second to reduce annular dimensions and tricuspid regurgitation. Image-guided using fluoroscopy and 2D/3D echocardiography on a beating heart without cardiopulmonary bypass. Intended for patients with tricuspid regurgitation who are ineligible for open-heart surgery. Currently an investigational device.
  • MIA-M Percutaneous Mitral Annuloplasty System Percutaneous annuloplasty system for mitral valve repair that places permanent cardiac implants into the mitral annulus for patients with Grade 2 or greater functional mitral regurgitation. Uses a closed-chest, beating-heart, transcatheter technique via transvenous, transseptal approach through the femoral vein. Built on the same PolyCor anchor and 12F catheter platform as MIA-T.
  • PolyCor™ Anchors Proprietary ultra-low mass, biocompatible polymeric anchors specifically designed for soft-tissue cardiac applications. Deploy from catheter-based delivery systems in 4/1000ths of a second, create secure purchase in tissue, comply with wall-motion, do not back out, and include radiopaque markers for visibility on imaging. Function as the foundational anchoring component of MID's transcatheter annuloplasty systems.

Quantifiable outcome

  • Significant reductions in annular dimensions and tricuspid regurgitation achieved acutely with MIA-T are durable at one-year follow-up
  • +2 more outcomes

Companies that use Micro Interventional Devices

Customer profile

Segments1 record

Ideal customer profiles1 record

Micro Interventional Devices technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Micro Interventional Devices partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Neovasc, Inc.minorOthers · 20 February 2019MID reached a settlement agreement with Neovasc, Inc. in February 2019. This was a legal settlement rather than a commercial partnership.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Micro Interventional Devices competitors and assessment

Company assessment

Broad incumbents

  • Abbott: Abbott markets the TriClip transcatheter tricuspid repair system (FDA-approved) and the MitraClip system for mitral repair — directly comparable transcatheter valve repair products targeting the same patient populations and delivered via similar percutaneous catheter approaches.
  • Edwards Lifesciences: Edwards has the Cardioband tricuspid repair system and the PASCAL mitral repair platform, making it one of the largest and most established incumbents in the percutaneous tricuspid and mitral repair space where MID competes.
  • Medtronic: Medtronic is a broad incumbent in structural heart with the Intrepid transcatheter mitral valve replacement program and a large interventional cardiology salesforce, competing for the same hospital budgets and structural heart programs as MID's MIA-T and MIA-M.
  • Boston Scientific: Boston Scientific is a broad medtech incumbent that has invested in structural heart programs (including transcatheter mitral investments) and serves the same hospital cardiology and cardiac surgery customers that MID targets with its TCR platform.

Direct peers

  • Cardiac Dimensions: Cardiac Dimensions develops the Carillon percutaneous annuloplasty system for functional mitral regurgitation — a near-direct competitor to MID's MIA-M, addressing the same indication via a transcatheter coronary sinus-based annuloplasty approach.
  • 4Tech Cardio: 4Tech Cardio is developing transcatheter tricuspid annuloplasty technology (Cardioband predecessor / similar percutaneous annular repair approach), making it a direct competitor in the same MIA-T category with overlapping clinical trial timelines and indications.
  • NeoChord: NeoChord develops transcatheter chordal repair technology for mitral regurgitation (DS1000 system via transapical delivery) — a direct peer in the percutaneous mitral repair space targeting the same pathology with a different mechanical approach.

Emerging players

  • Ancora Heart: Ancora Heart is developing the AccuCinch transcatheter ventricular repair system for functional mitral regurgitation, an emerging player in the percutaneous mitral repair category with overlapping clinical positioning to MIA-M.
  • Cardiovalve: Cardiovalve (acquired by Venus Medtech) is developing a transcatheter tricuspid and mitral valve replacement technology — an emerging player in the structural heart repair category overlapping MID's MIA-T and MIA-M indications.
  • Polaris Cardiovascular: Polaris Cardiovascular develops transcatheter tricuspid repair devices, an emerging competitor in the same percutaneous tricuspid annular repair space where MID's MIA-T competes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Micro Interventional Devices social profiles

Digital presence

Micro Interventional Devices compliance and trust

Trust signal

Compliance1 record

Micro Interventional Devices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micro Interventional Devices leadership team

Management profile

Number of profiles

Profiles6 records

Micro Interventional Devices funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micro Interventional Devices M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micro Interventional Devices

What does Micro Interventional Devices do?

Micro Interventional Devices (MID) designs, manufactures and commercializes catheter-based technologies for transcatheter cardiac repair (TCR) of structural heart disease. Its core products are the MIA-T Percutaneous Tricuspid Annuloplasty System and the MIA-M Percutaneous Mitral Annuloplasty System, both built on a proprietary PolyCor anchor platform deployed through a 12F catheter to replicate surgical annuloplasty on a beating heart without cardiopulmonary bypass. The MIA-T system has FDA Breakthrough Device Designation and IDE approval for a US pivotal trial, while European clinical trial data from the STTAR study covers 31 treated patients to date.

Is Micro Interventional Devices a public or private company?

Micro Interventional Devices is a private company. It is classified as venture growth investor backed and is currently operating.

When was Micro Interventional Devices founded?

Micro Interventional Devices was founded in 2010. It employs 11 to 50 people.

Where is Micro Interventional Devices based?

Micro Interventional Devices is headquartered in Newtown, United States, in the North America region.

How does Micro Interventional Devices make money?

One revenue line is on record: medical Device Sales.

Who are Micro Interventional Devices's main competitors?

Broad incumbents on record are Abbott, Edwards Lifesciences, Medtronic and Boston Scientific. Direct peers are Cardiac Dimensions, 4Tech Cardio and NeoChord. Emerging players are Ancora Heart, Cardiovalve and Polaris Cardiovascular.

Does Micro Interventional Devices have an API?

No public API is recorded for Micro Interventional Devices.

What industry is Micro Interventional Devices in?

Micro Interventional Devices's product category is Structural Heart Repair Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogMicro Interventional Devices Receives FDA Approval of the STTAR-US IDE Pivotal Trial for its MIA™-T Percutaneous Tricuspid Annuloplasty SystemMicro Interventional Devices received FDA approval for its MIA-T tricuspid annuloplasty system, allowing the STTAR-US pivotal trial to begin. The trial uses PolyCor anchors to treat functional tricuspid regurgitation, addressing 1.6 million US patients. The global market is projected to exceed $3 billion annually by 2027.BioSpaceMicro Interventional Devices Receives FDA Approval of the STTAR-US IDE Pivotal Trial for its MIA™-T Percutaneous Tricuspid Annuloplasty SystemMicro Interventional Devices (MID) received FDA approval for its Investigational Device Exemption (IDE) to begin the STTAR-US pivotal trial of the MIA-T percutaneous tricuspid annuloplasty system at U.S. hospitals. The device uses proprietary PolyCor anchors deployed via 12F catheters to treat tricuspid regurgitation by reducing annular area. An estimated 1.6 million people in the U.S. suffer from tricuspid regurgitation with only a small percentage eligible for surgical treatment, and the global TTVr market is projected to exceed $3 billion annually by 2027.PR NewswireGlobal Prosthetic Heart Valve Market to 2031 - Featuring Abbott Laboratories, Medtronic, Boston Scientific and Micro Interventional Devices Among OthersResearch and Markets released a global market report on the prosthetic heart valve industry, estimating the market was valued at $6,889.3 million in 2021 and is projected to reach $19,738.23 million by 2031, growing at a CAGR of 11.1%. Key growth drivers include an aging population, increasing heart surgeries, rising healthcare expenditure, and demand for minimally invasive procedures, while restraints include reimbursement concerns, high development costs, and stringent regulations. The report profiles major industry players including Abbott Laboratories, Medtronic, Boston Scientific, and Edwards Lifesciences, and segments the market by product type and region.MedicaltubingandextrusionMicro Interventional Devices tricuspid annuloplasty system wins FDA breakthrough device designationMicro Interventional Devices received FDA breakthrough device designation for its MIA-T percutaneous tricuspid annuloplasty system, which treats moderate to severe tricuspid regurgitation. The company submitted 12-month safety and performance data from six European sites, reporting significant TR reductions and no device-related mortality. It expects CE and IDE approvals to initiate a U.S. pivotal trial by year-end.PR NewswireFDA Grants Micro Interventional Devices, Inc. Breakthrough Device Designation for the MIA™-T Percutaneous Tricuspid Annuloplasty SystemThe U.S. Food and Drug Administration (FDA) granted Micro Interventional Devices (MID) Breakthrough Device Designation for its MIA-T Percutaneous Tricuspid Annuloplasty System, a catheter-based treatment for moderate-severe tricuspid regurgitation. The designation enables more frequent FDA interactions and is expected to expedite the clinical trial process as the company pursues US commercialization, with the STTAR European study showing significant two and three grade TR reductions maintained at 12-month follow-up with no device or procedure-related mortality, stroke, or myocardial infarction. MID anticipates receiving both CE Mark approval and IDE approval to initiate the STTAR-US pivotal study by the end of 2021.PR NewswireFDA erteilt Micro Interventional Devices, Inc. Breakthrough Device Designation für das MIA™-T Percutaneous Tricuspid Annuloplasty SystemMicro Interventional Devices (MID) received Breakthrough Device Designation from the U.S. FDA for its MIA-T Percutaneous Tricuspid Annuloplasty System, a 12F catheter-based device designed to treat moderate tricuspid regurgitation. The device demonstrated positive 12-month follow-up data from the European STTAR study with no device or procedure-related mortality, stroke, or myocardial infarction, and the company expects to obtain CE Mark and IDE approval by the end of 2021. The designation enables more frequent FDA interactions to accelerate the U.S. clinical trial and commercialization process, with over 1.6 million people in the U.S. suffering from tricuspid regurgitation.PR NewswireLa FDA accorde à Micro Interventional Devices, Inc. la désignation de dispositif révolutionnaire pour le système d'annuloplastie tricuspide percutanée MIA™-TMicro Interventional Devices (MID) has received Breakthrough Device Designation from the US FDA for its MIA-T percutaneous tricuspid annuloplasty system, which treats moderate to severe tricuspid regurgitation via a 12F catheter. The designation enables more frequent and accelerated interactions with the FDA, including sprint discussions and regular progress reviews, to facilitate US clinical trial enrollment. The company expects to receive both CE marking and IDE approval to launch the STTAR-US pivotal study by end of 2021, with 12-month follow-up data from the European STTAR study showing significant TR reductions and no device-related mortality, stroke, or myocardial infarction.PR NewswireLa FDA concede a Micro Interventional Devices, Inc. la designación de dispositivo innovador para MIA™ -TThe FDA granted Micro Interventional Devices, Inc. (MID) Breakthrough Device Designation for its MIA™-T percutaneous tricuspid annuloplasty system, which treats moderate-to-severe tricuspid regurgitation via a 12F catheter. The designation will facilitate more frequent and timely FDA interactions to accelerate the US clinical trial process, as the company pursues both CE Mark approval and IDE approval to begin the STTAR-US pivotal study by end of 2021. Clinical data from the European STTAR study showed sustained two-to-three grade reductions in tricuspid regurgitation at 12 months with a 36% average improvement in quality-of-life scores and no reported device-related mortality, stroke, or myocardial infarction.PR NewswireMicro Interventional Devices, Inc.™ gibt die Einreichung der technischen Dokumentation für die CE-Kennzeichnung für das MIA-T™ Perkutane Trikuspidale Annuloplastie-System bekanntMicro Interventional Devices, Inc. (MID) submitted technical documentation for CE marking of its MIA-T Percutaneous Tricuspid Annuloplasty System to a Notified Body, with approval expected by the end of 2021. The submission is based on one-year follow-up data from the STTAR clinical study conducted at six European hospitals, showing sustained reduction in annular dimension and tricuspid regurgitation with no device- or procedure-related deaths, strokes, or myocardial infarctions. MID is also working with the FDA on an Investigational Device Exemption to begin a 30-site multicenter STTAR study in the United States, followed by a Premarket Approval application.PR NewswireMID anuncia la solicitud de marca CE para el sistema MIA-T™Micro Interventional Devices, Inc. (MID) has announced the submission of technical documentation for CE marking of its MIA-T™ system for percutaneous tricuspid annuloplasty, aiming for approval to market in the European Union. This submission includes a year of follow-up data from the STTAR clinical study and highlights the potential of the system to provide treatment options for patients currently deemed too high-risk for traditional surgical procedures. MID anticipates receiving CE approval in 2021, which would mark a significant growth phase for the company.